3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
68
Recurrence
17
Neoplasms
5
Immunoglobulin Light-chain Amyloidosis
5
Neoplasms, Plasma Cell
4
Lymphoma, Large B-Cell, Diffuse
3
Renal Insufficiency
2
Plasmacytoma
2
Myeloproliferative Disorders
2
Chromosome 17 deletion
2
Amyloidosis
2
Thrombocytosis
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Paraproteinemias
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Malignant Plasma Cell Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia, Plasma Cell
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
venetoclax
3
ibrutinib
3
fludarabine phosphate
3
pomalidomide
2
Whole-Body Irradiation
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Dexamethasone
2
pembrolizumab
1
fludarabine
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
acalabrutinib
1
Tacrolimus
1
Nivolumab
1
Melphalan
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cyclosporine
1
Cyclophosphamide
1
Carmustine
1
Atorvastatin
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Chromosome 17 deletion
×
pomalidomide
×
Clear all
NCT01745640
2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2
Completed
63 enrolled
NCT04124497
2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2
Active not recruiting
45 enrolled